عوامل خطرزا در سندروم تخمدان پلی کیستیک

نوع مقاله: اصیل پژوهشی

نویسندگان

1 استادیار گروه فیزیولوژی، مرکز تحقیقات بهداشت باروری ولیعصر (عج)، بیمارستان ولیعصر (عج)، دانشگاه علوم پزشکی تهران، تهران، ایران

2 مربی گروه پزشکی اجتماعی، دانشکده پزشکی، دانشگاه علوم پزشکی فسا، فسا، ایران.

3 کارشناس ارشد روانشناسی، مرکز بهداشت باروری ولیعصر (عج)، بیمارستان ولیعصر (عج)، دانشگاه علوم پزشکی تهران، تهران، ایران.

4 کارشناس ارشد مامایی، مرکز بهداشت باروری ولیعصر (عج)، بیمارستان ولیعصر (عج)، دانشگاه علوم پزشکی تهران، تهران، ایران.

چکیده

مقدمه: سندروم تخمدان پلی کیستیک (PCOS) شایع ترین اختلال هورمونی زنان، یک بیماری پیچیده با علت و
معلول ناشناخته است. این بیماری با اختلالات دستگاه تولید مثل شامل عدم تخمک گذاری مزمن، افزایش آندروژن و
تخمدان های پلی کیستیک مشخص می شود. میزان شیوع آن در بین زنان جوان 4-18% می باشد. مطالعه حاضر با
هدف بررسی عوامل خطرزا در بروز سندروم تخمدان پلی کیستیک انجام شد.
روشکار: این مطالعه توصیفی- تحلیلی در سال 1389 بر روی 81 زن مبتلا به سندروم تخمدان پلی کیستیک مراجعه
کننده به مرکز تحقیقات بهداشت باروری بیمارستان ولی عصر (عج) انجام شد. ابزار گردآوری داده ها پرسشنامه ای بود
که شامل سؤالات مربوط به اطلاعات جمعیت شناسی و استرس می شد. تجزیه و تحلیل داده ها با استفاده از نرم افزار
آماری SPSS (نسخه 13) و آزمون های تی و کای دو انجام شد و p<0/05 از نظر آماری معنی دار تلقی شد.
یافتهها: نتایج مطالعه نشان داد که 45 نفر (55/6%) زنان دچار هیرسوتیسم، 48 نفر (59/3%) دارای شاخص توده
بدنی بالاتر از 29 ،26 نفر (35/8%) مبتلا به استرس زیاد و 12 نفر (14/8%) دارای استرس بسیار زیاد و نیازمند به
مداخله فوری بودند. بین علامت تنش عصبی (هیستری) با هیرسوتیسم (p=0/011) و بین توده بدنی بالا و مصرف
دارو (p=0/004) ارتباط آماری معنی داری وجود داشت.
نتیجهگیری: در بیماران مبتلا به سندروم تخمدان پلی کیستیک با علامت هیرسوتیسـم و شـاخص تـوده بـدنی بـالا،
علامت تنش عصبی بیشتری مشاهده می شود. 

کلیدواژه‌ها


عنوان مقاله [English]

Risk Factors in Polycystic Ovary Syndrome

نویسندگان [English]

  • Farideh Zafari Zangeneh 1
  • Mohammad Mehdi Naghizadeh 2
  • Nasrine Abedinia 3
  • Fedyeh Haghollahi 4
1 Assistant Professor of Physiology, Vali-e-Asr Reproductive Health Research Center, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
2 Lecturer of Community Medicine, Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran.
3 M.Sc. of Clinical Psychologist, Vali-e-Asr Reproductive Health Research Center, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
4 M.Sc. of Midwifery, Vali-e-Asr Reproductive Health Research Center, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
چکیده [English]

Introduction: Polycystic ovary syndrome (PCOS), the most common female endocrine disorder, is a complex disease with unknown etiology. PCOS is characterized by reproductive disturbances including chronic anovulation, hyperandrogenism, and polycystic ovaries. Its prevalence is 4% to 18% among young women. This study aimed to determine the risk factors in PCOS.
Methods: In this descriptive-analytic study, 81 patients with PCOS referred to Vali-e-Asr Hospital, Reproductive Health Research Center, were studied. A questionnaire included demographic and stress information was used for data collection. Statistical analyses were performed by using SPSS (13 version) software, T-test, and chi- square. p<0.05 was considered statistically significant.
Results: The results of this study showed that 45 women (55.6%) suffered from hirsutism, 48 (59.3%) women BMI higher than 26, high stress in 29 women (35.8%), very high stress and in need of immediate intervention in12 women (14.8%). A significant relationship was found between hysteria and hirsutism (p=0.011) and between high BMI and drug abuse (p=0.004).
Conclusion: PCOS patients with hysteria signs and high BMI showed more nervous tensions.

کلیدواژه‌ها [English]

  • Hirsutism
  • Hysteria
  • Obese
  • Overweight
  • Polycystic ovary syndrome
1. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome.
Cochrane Database Syst Rev 2011 Feb;16(2):CD007506. Review.
2. Fleming R, Hopkinson ZE, Wallace AM, Greere IA, Sattar N. Ovarian function and metabolic factors in women
with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial, J Clinical
Endocrinol Metab 2002 Feb;87(2):569-74.
3. Dahlgrene E, Janson PO, Jahansson S, Lapidus L, Lindstedt G, Tengborn L. Hemostatic and metabolic variables
in women with polycystic ovary syndrome. Fertil Steril 1994 Mar;61(3):455-60.
4. Hernández-Valencia M, Hernández-Rosas M, Zárate A. [Care of insulin resistance in polycystic ovary
syndrome] [Article in Persian]. Ginecol Obstet Mex 2010 Nov;78(11):612-6.
5. Stener-Victorin E, Ploj K, Larsson BM, Holmäng A. Rats with steroid-induced polycystic ovaries develop
hypertension and increased sympathetic nervous system activity. Reprod Biol Endocrinol 2005 Sep;7(3):44.
6. Lara HE, Dorfman M, Venegas M, Luza SM, Luna SL, Mayerhofer A, et al. Changes in sympathetic nerve
activity of the mammalian ovary during a normal estrous cycle and in polycystic ovary syndrome: studies on
norepinephrine release. Microsc Res Tech 2002 Dec 15;59(6):495–502.
7. Chen C, Smothers J, Lange A, Nestler JE, Strauss Iii JF, Wickham Iii EP. Sex hormone-binding globulin
genetic variation: associations with type 2 diabetes mellitus and polycystic ovary syndrome. Minerva Endocrinol
2010 Dec;35(4):271-80. Review.
 
8. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment
of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a
consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin
Endocrinol Metab 2010 May;95(5):2038-49.
9. Wang ET, Calderon-Margalit R, Cedars MI, Daviglus ML, Merkin SS, Schreiner PJ, et al. Polycystic ovary
syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol 2011 Jan;117(1):6-13.
10. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001 Nov-Dec;7(6):522-5.
11. Nitsche K, Ehrmann DA. Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome.
Best Pract Res Clin Endocrinol Metab 2010 Oct;24(5):717-30. Review.
12. Jakubowski L. [Genetic aspects of polycystic ovary syndrome] [Article in Polish]. Endokrynol Pol 2005 MayJun;56:285-93.
13. Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence
from experimental, clinical, and genetic association studies. J Clin Endocrinol Metab 2006 May;91(5):1660-6.
14. Alemzadeh R, Kansra AR. New adolescent polycystic ovary syndrome perspectives. Minerva Pediatr 2011
Feb;63(1):35-47.
15. Schmid SM, Schultes B. [Disturbed sleep as risk factor for metabolic syndrome]. Internist (Berl) 2011
Apr;52(4):383-8.
16. Van Cauter E, Spiegel K, Tasali E, Leproult R. Metabolic consequences of sleep and sleep loss. Sleep Med
2008 Sep;9 Suppl 1:S23-8. Review.
17. Morselli L, Leproult R, Balbo M, Spiegel K. Role of sleep duration in the regulation of glucose metabolism and
appetite. Best Pract Res Clin Endocrinol Metab 2010 Oct;24(1):687-702. Review.
18. Tasali E, Leproult R, Spiegel K. Reduced sleep duration or quality: relationships with insulin resistance and
type2 diabetes. Prog Cardiovasc Dis 2009 Mar-Apr;51(5):381-91.
19. Benson S, Hahn S, Tan S, Mann K, Janssen OE, Schedlowski M, et al. Prevalence and implications of anxiety in
polycystic ovary syndrome: results of an internet-based survey in Germany. Hum Reprod 2009 Jun;24(6):1446-
51
20. Jedel E, Waern M, Gustafson D, Landén M, Eriksson E, Holm G, et al. Anxiety and depression symptoms in
women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod
2010 Feb;25(2):450-6.
21. Deeks A, Gibson-Helm M, Teede H. Anxiety and depression in polycystic ovary syndrome: a comprehensive
investigation. Fertil Steril 2010 May 1;93(7):2421-3.
22. Må nsson M, Holte J, Landin-Wilhelmsen K, Dahlgren E, Johansson A. Women with polycystic ovary syndrome
are often depressed or anxious--a case control study. Psychoneuroendocrinology 2008 Sep;33(8):1132-8.
23. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health 2011 Feb
8;3:25-35.
24. Rotterdom ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic
criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004
Jan;19(1):41-7.
25. Linda V. Berens. Understanding yourself questionnaire 2001, SIGNET Publication, translator: Rezakhani
Ziaeddin.
26. Gan EH, Quinton R. Physiological significance of the rhythmic secretion of hypothalamic and pituitary
hormones. Prog Brain Res 2010;181:111-26.
27. Galvão Mde O, Sinigaglia-Coimbra R, Kawakami SE, Tufik S, Suchecki D. Paradoxical sleep deprivation
activates hypothalamic nuclei that regulate food intake and stress response. Psychoneuroendocrinology 2009
Sep;34(8):1176-83.
28. Bordini B, Littlejohn E, Rosenfield RL. Blunted sleep-related luteinizing hormone rise in healthy premenarcheal
pubertal girls with elevated body mass index. J Clin Endocrinol Metab 2009 Apr;94(4):1168-75.
29. Benedict C, Kern W, Schmid SM, Schultes B, Born J. Hallschmid M. Early morning rise in hypothalamicpituitary-adrenal
activity: a role for maintaining the brain's energy balance. Psychoneuroendocrinology 2009
Apr;34(3):455-62.
30. Martínez-Bermejo E, Luque-Ramírez M, Escobar-Morreale HF. Obesity and the polycystic ovary syndrome.
Minerva Endocrinol 2007 Sep;32(3):129-40.
31. Zabulienė L, Tutkuvienė J. [Body composition and polycystic ovary syndrome] [Article in Lithuanian].
Medicina (Kaunas) 2010;46(2):142-57.
32. Faloia E, Canibus P, Gatti C, Frezza F, Santangelo M, Garrapa GG, et al. Body composition, fat distribution and
metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest 2004
May;27(5):424-9.
33. Coffey S, Mason H. The effect of polycystic ovary syndrome on health-related quality of life. Gynecol
Endocrinol 2003 Oct;17(5):379-86.
34. Deeks AA, Gibson-Helm ME, Paul E, Teede HJ. Is having polycystic ovary syndrome a predictor of poor
psychological function including anxiety and depression? Hum Reprod 2011 Jun;26(6):1399-407.
35. Borkovec TD. Living in a state of worry can cause anxiety, and depression, as well as ruin the present. Worry
does take the pain out of tomorrow; it causes one to be prepared today. -Anonymous. Life in the future versus
life in the present. Clin Psychol Sci Pract 2002;9:76–80